Despite growing evidence for platelets as active players in infection and immunity, it remains unresolved whether platelets contribute to, or are key elements in the development of neuroinflammation. Using the experimental autoimmune encephalomyelitis (EAE) model of multiple sclerosis, we identified platelet accumulation in the circulation by 7-day postinduction (dpi), ahead of clinical onset which occurs at 13-14 dpi. By inducing platelet depletion between 7 and 16 dpi, we demonstrate an association between platelet accumulation in the spinal cord and disease development. Additionally, we provide evidence for platelet infiltration in the white and gray matter parenchyma, but with different outcomes. Thus, while in white matter platelets are clearly associated with lesions, in gray matter large-scale platelet infiltration and expression of the plateletspecific molecule PF4 are detectable prior to T cell entry. In the retina, platelet accumulation also precedes clinical onset and is associated with significant increase in retinal thickness in experimental relative to control animals. Platelet accumulation increases over the disease course in this tissue, but without subsequent T cell infiltration. These findings provide definitive confirmation that platelet accumulation is key to EAE pathophysiology. Furthermore, they suggest an undescribed and, most importantly, therapeutically targetable mechanism of neuronal damage.
INTRODUCTION
Although platelets have been investigated in the context of homeostasis and thrombosis for decades, their role in inflammation emerged relatively recently (1) (2) (3) . Platelets express a plethora of receptors and can release a wide range of inflammatory mediators that are not associated with their classical roles but instead with inflammation, immunity, and tissue repair (4, 5) . These, presumably, underlie their capacity for intimate cross-talk with inflammatory cells (5) . To date, platelets have been implicated in the etiology of infection (6) , inflammatory diseases including rheumatoid arthritis (7) and atherosclerosis (8) , as well as neuropathologies, particularly stroke (9, 10), Alzheimer disease (11) (12) (13) and, more recently, multiple sclerosis (MS) (14) .
Evidence for platelet involvement in MS began to emerge following the demonstration of chronic platelet activation in peripheral blood of patients (15) as well as expression of the platelet-specific receptor CD41 in microarrays of chronic lesions (16) . Investigations based on animal models have relied on the use of murine experimental autoimmune encephalomyelitis (EAE), an inflammatory central nervous system (CNS) demyelinating disease commonly used as an MS model (17, 18) . MS and EAE are distinct diseases, but EAE has proven very valuable in providing proof of concept for mechanisms underlying MS pathogenesis. A study by Langer et al indicated that platelets contribute to EAE pathogenesis by exacerbating rather than driving CNS inflammation (19) . Thus, platelet depletion or blockade of platelet adhesion receptors, including GPIba and GPIIb/IIIa resulted in amelioration, but not complete elimination of disease. This, however, conflicts with more recent evidence suggestive of an early role for platelets in the expansion and differentiation of CD4 T cells during neuroinflammation (20) and atherosclerosis (21) . Finally, a role for platelets in neuroinflammation was further consolidated by evidence that platelet recognition of sialated gangliosides in lipid rafts on the surface of astrocytes and neurons was essential for EAE development (22) . The present study was aimed at definitively establishing whether platelets contribute, or are essential, to the development of neuroinflammation. We first identified the critical timing of platelet accumulation in the peripheral circulation following EAE induction. We then showed absence of disease development and spinal cord lesions when platelet depletion was initiated at this specific time point. Subsequently, because visual dysfunction is a common manifestation of MS (23), we examined the association between platelets and evidence of pathology in the retina. Our data show that, in addition to disease exacerbation as demonstrated in the literature (19) , platelets play a driving role in the development of inflammation.
MATERIALS AND METHODS
All experimentation was approved by the La Trobe University Animal Ethics Committee and performed in strict accordance with regulations set by the National Health and Medical Research Council of Australia.
EAE Induction and Surveillance
EAE was induced in female C57Bl/6 mice (9-12 weeks of age) with MOG peptide and disease progression monitored on a daily basis, as described (24) . Control groups included normal and vehicle-only mice, sex, and age-matched. Mice were randomly assigned to each group.
Platelet Depletion
Platelet depletion was achieved by intravenous injection of platelet depletion antibody cocktail, containing a rat monoclonal antibody against CD42b (R300, EMFRET Analytics GMBH & Co KG, Eibelstadt, Germany) at a dose of 0.5 mg/ kg body weight. A nonimmune rat Ig preparation (C301, Emfret Analytics) was administered at the same concentration as control. Submandibular bleeds were carried out 24 hours after each injection of the R300 or C301 preparations, for estimations of platelet numbers using an automated hematology analyzer, Sysmex XS-1000i (Sysmex America, Inc., Mundelein, IL).
Tissue Preparations
For analyses of spinal cord tissues, mice were perfused with phosphate-buffered saline ([PBS] 10 mM sodium phosphate, 150 mM NaCl, pH 7.4) followed by 4% w/v paraformaldehyde in PBS, by transcardiac perfusion. Tissues were postfixed for a minimum of 4 hours in paraformaldehyde prior to further handling. For investigations of the retina, eyes were enucleated immediately following death and fixed in paraformaldehyde for 30 minutes, then transferred to 70% ethanol. This was done to ensure that platelet leakage did not result from excessive perfusion pressure. Flatmounts were prepared as described (25) . For histological staining, tissues were paraffin embedded, sections cut at 7-lm thickness, then stained with hematoxylin and eosin (H&E) or cresyl violet acetate (Nissl stain) according to standard protocols. Lesion topography and severity were recorded with a Nikon Ti Eclipse microscope (Nikon Corporation, Tokyo, Japan). For confocal microscopy, cryostat sections were cut at 30 lm in the horizontal plane from the spinal cord and the coronal plane from eyeballs and stored in cryoprotectant (26) at À20 C until required.
Immunochemistry and Confocal Microscopy
Immunochemistry was performed as described (27, 28) . Primary antibodies included a rat monoclonal anti-CD42b cocktail used at 1:100 (R300), a mouse monoclonal anti-hypophosphorylated neurofilament protein, at 1:400 (clone SMI-32; Sternberger Monoclonals, Inc., Lutherville, MD), rabbit polyclonal anti-CD41 at 1:100 (GTX76011; GeneTex, Inc., Irvine, CA), rabbit polyclonal anti-albumin at 1:400 (A 0001; DAKO, Glostrup, Denmark), rabbit polyclonal anti-GFAP at 1:400 (Z0334; DAKO), rabbit polyclonal anti-MBP at 1:200 (A0623; DAKO), rabbit polyclonal anti-Iba1 at 1:300 (019-19741; Wako Chemicals USA, Inc., Richmond, VA), rabbit polyclonal anti-CD31 at 1:500 (Abcam, Cambridge, UK), and goat polyclonal anti-PF4 at 1:100 (AF595; R&D Systems, Inc., Minneapolis, MN). Detection was performed using the appropriate secondary antibodies conjugated to AlexaFluor 488 or AlexaFluor 594 (Thermo Fisher Scientific, Inc., Waltham, MA), or where amplification was required, with the appropriate biotinylated secondary antibody followed by streptavidin AlexaFluor 488, or streptavidin AlexaFluor 555. Where necessary, blood vessels were stained using fluorescent-conjugated lectin from Lycopersicon esculentum (Sigma-Aldrich, St. Louis, MO). Nuclei were stained with 4 0 ,6-diamidino-2-phenylindole (DAPI) (Vector Laboratories, Inc., Burlingame, CA). Immunofluorescence was detected on a Zeiss LSM 780 confocal microscope and images captured using the Zen 2011 (Carl Zeiss AG, Oberkochen, Germany) software. The Imaris Scientific 3D/4D image Analysis Workstation (Bitplane AG, Zurich, Switzerland) was used to render the z-stack captured data from the samples as 3D images. The Imaris software Version 7.5 was used, along with the MeasurementPro (Bitplane) module to capture and measure the density of fluorescently stained voxels (volumetric pixels).
Estimation of Retinal Thickness
Normal, vehicle-only, and MOG -induced mice groups were used (n ¼ 4 per group). Eyeballs were completely sectioned in the coronal plane at 10-mm thickness from the caudal (optic nerve) to rostral (pupil) direction. Three regions separated by 100 mm were reproducibly selected, with 6 sections per region and 10 measurements per section. Section thickness (spanning outer segments of the photoreceptor layer to outer surface of the retinal ganglion cell layer [mm]) was measured from phase-contrast images and analyzed by Image J (National Institutes of Health, Bethesda, MD).
Quantitative PCR
Platelet and T-cell levels in the spinal cord were estimated by quantitative PCR (qPCR) analysis of CD41 and CD3 mRNA expression, respectively, over a time course ranging from 8-to 16-day postinduction (dpi), corresponding to the times at which circulatory platelet counts were obtained. Following total RNA extraction using the RNeasy Lipid Tissue Mini Kit (QIAGEN, Venlo, Limburg, Netherlands) and cDNA synthesis using the Superscript Kit (Qiagen), quantitative realtime PCR reactions were run on CFX96 Real-time System (Bio-Rad, Hercules, CA). The sequence for the forward primer for CD41 was TTTCTGCAGCCTAAGGGCC and reverse primer GGCAGCCACAGCAATATCATT (29) . For CD3, the sequence for the forward primer was ATGCGGTGGAA-CACTTTCTGG and reverse primer GCACGTCAACTCTA-CACTGGT (30) . Amplification reactions were performed using RT2 SYBR Green qPCR Master mix (QIAGEN) and 1 lM primers in a 10-ll volume. All reactions began with initial activation at 95 C for 10 minutes, followed by 45 cycles of 95 C for 15 seconds, 59 C for 20 seconds and 72 C for 15 seconds and a final extension step at 72 C for 7 minutes. Dissociation curves indicated a unique amplified product for each primer set as expected, which was verified by agarose gel analysis. The Ct values were generated by the Bio-Rad CFX Manager software and imported into Microsoft Excel (Microsoft Corporation, Redmond, WA) for conversion to fold expression relative to unit mass (1 lg total RNA).
Statistical Analysis
Statistical significance of results was determined using the Student's t-test (2-sample assuming unequal variances and normal distribution) on Microsoft Excel. Outcomes were considered to be significant when the p value (1-tailed) was <0.05, highly significant when p < 0.01 and extremely significant when p < 0.001. In all statistical analyses, calculated t-values were below critical t-limit. At least 8 mice per group were used for the platelet depletion experiments (2 independent experiments) and 3-4 per group for qPCR experiments and histological evaluations. These sample sizes were based on previous experience which showed statistically significant differences between experimental, vehicle-only, and normal groups. No mice were excluded from the analyses.
RESULTS

Platelets Accumulation Begins During the Preclinical Stage of EAE
To determine the relationship between platelets and EAE development, experimentation was based on the MOG -induced C57Bl/6 variant (27) . We first performed platelet counts in blood over the disease course, from preclinical stage to a score of 3 ( Fig. 1 ). Results showed a gradual rise in platelet numbers from 0 to 7 dpi, followed by a sudden and significant increase at 7-8 dpi before reaching a plateau at 9 dpi, which was maintained until experimental end-point. These data identify the timing of platelet accumulation ahead of that of clinical onset, which occurs at 13-14 dpi in this EAE variant ( Fig. 2A) . preparations were administered to MOG 35-55 -induced and vehicle-only groups, over the 2-6, 7-11, and 11-15 dpi (3 injections) periods (colored arrows and boxes) and clinical scores (A) and percentage weight loss (B) recorded. EAE was eliminated and % weight loss significantly reduced only over the 7-15 dpi treatment period (5 injections) (**p < 0.01, ***p < 0.001). Error bars ¼ mean 6 SEM, n ¼ 8 per group. (C) Left: Representation of spinal cord regions examined in Ci-Cvi; tissues were collected at experimental end-point (16 dpi) and representative H&E sections shown. Perivascular lesions were absent in the 7-15 dpi MOG -induced/R300-treated group (Ci, Cii), normal, and vehicle-only groups (not shown), but severe in the MOG induced/C301-treated group (dotted line, Civ-v). BV, blood vessel; WM, white matter; VF, ventral funiculus. Lesions are minimal in the MOG 35-55 -C57Bl/6 gray matter (GM) (Ciii ¼ R300-treated, Cvi ¼ C301-treated). (D) and (E) Parenchymal accumulation of CD41 and CD3 in MOG -induced/no further treatment group, from 8 to 16 dpi using vehicle-only and MOG -induced/ R300-treated mice as control (treatment over 7-15 dpi, tissues sampled at day 16). qPCR analysis of cDNA generated from PBSperfused spinal cord (SC) RNA. In MOG -induced/no further treatment mice peak of CD41 accumulation was at 12 dpi, before returning to intermediate levels. In the same group (E), CD3 accumulation increased slowly from 12 to 14 dpi, peaking at 16 dpi. Expression fold-change values are relative to vehicle-only. Note highly reduced CD3 expression in the MOG induced/R300-treated group (PD) at 16 dpi (E).
mean clinical scores at experimental end-point, nor on disease duration, relative to the MOG 35-55 -induced/C301-treated group ( Fig. 2; Table) . The only significantly different measure was that of cumulative disease scores in the 2-6 and 11-15 dpi depletion groups relative to the MOG 35-55 -induced/C301-treated group (p < 0.05) (Table) . Irrespective of treatment regimen, platelet depletion with R300 was >98% (Table) , and platelet numbers recovered rapidly within 48 hours of cessation of treatment, exceeding those of the MOG 35-55 -induced/C301-treated group (Fig. 1) . Strikingly, when platelet depletion was initiated at 7 dpi, but sustained until 15 dpi, clinical EAE was essentially abolished (p < 0.0000015, Fig. 2A ; Table) and percentage weight loss (Fig. 2B ) significantly reduced (p < 0.01), compared with the MOG 35-55 -induced/C301-treated group. The above observations were supported by H&E staining of spinal cord tissues at experimental end-point (Fig. 2C) , showing no perivascular inflammation in the 7-15 dpi MOG -induced/ R300-treated group (Fig. 2C i-ii) , but severe lesions in the MOG 35-55 /R300-treated groups with short-term depletion initiated at 2, 7, or 11 dpi, or other MOG-induced control groups (Fig. 2C iv-v) .
We also performed immunochemical evaluation of other parameters of neuroinflammation in the same tissues (27) Data Fig. S1 ). These parameters were found to be elevated in experimental groups exposed to short-term platelet depletion, but not in the group where depletion was initiated at 7 dpi and maintained. We conclude that platelet depletion is highly effective when initiated at 7 dpi, namely, prior to clinical onset (28) and corresponding to the timing of significant rise in circulating platelet numbers (Fig. 1) . However, sustained depletion is required to completely eliminate EAE development.
Platelet Infiltrate the Spinal Cord Parenchyma Ahead of Lymphocytic Infiltration
Because of evidence of platelet association with MS and EAE lesions (19), we also investigated the parenchymal accumulation of platelets and T cells. This was achieved by qPCR analyses of the platelet marker CD41 and the T cell marker CD3 over the disease course using cDNA generated from PBS-perfused spinal cord tissue RNA. Tissues were sampled from 3 treatment regimens, namely, 1) MOG 35-55 -induced/no further treatment (5 time points, between 8 and 16 dpi), 2) MOG 35-55 -induced/R300-treated over the 7-15 dpi period (experimental end-point only), and 3) vehicle-only/R300-treated (end-point). Results showed rapid parenchymal accumulation of CD41 only in the MOG -induced/no further treatment group, beginning between 8 and 10 dpi and reaching maximum levels by 12 dpi, but decreasing to intermediate levels by experimental end-point (Fig. 2D) . CD3 accumulation was first observed in the same group between 10 and 12 dpi, and increased until 16 dpi (Fig. 2E) . On the other hand, CD3 accumulation was almost undetectable in cDNA isolated from plateletdepleted animals. No comparable changes in platelet, nor CD3 markers, were found in control groups. Thus, the peak of parenchymal platelet invasion preceded that of CD3 cells and platelet depletion was associated with absence of CD3 accumulation. These data suggest that platelet accumulation EAE was induced as described and vehicle-only and normal mice were used as controls. Platelet depletion was achieved by administration of anti-CD42b (R300) at a dosage of 0.5 mg/kg body weight every 48 hours, which resulted in depletion of over 98%. Different regimens were applied as shown, varying in the timing of initiation of platelet depletion and treatment duration (4 or 8 days). The resulting effects on timing of disease onset (clinical score !1.0), disease severity (determined by mean clinical score at experimental end point and mean cumulative score) are shown. Disease was completely abrogated only when depletion was initiated at 7 dpi and maintained, while weight loss in this group was significantly different from that of MOG -induced/C301 treated (p ¼ 0.002) and MOG -induced/R300-treated groups over shorter periods. † Represents a single mouse from this group which exhibited a score of 2 at 16 dpi. Error bars represent SEM and significance level *p 0.05, *p 0.01, ***p 0.001. NA, not applicable. drives CD3 cell recruitment into the parenchyma, rather than the reverse, and provide an explanation for the efficacy of platelet depletion when initiated from 7 dpi rather than clinical onset.
Platelets Infiltrate Both Gray and White Matter CNS
We verified the presence of platelets in the parenchyma by immunochemistry with combined anti-CD41 and antiCD42b. Confirmation that elements stained are platelets was provided by coincidence of staining, small size, and absence of nuclei in elements stained (Fig. 3B, C) . The small size of platelets precludes their early detection at time points identified by expression analysis; however, the timing of their earliest detection in the parenchyma differed between white and gray matter. In white matter, platelets were found by 12 dpi, generally in association with perivascular lesions (Figs. 3B, and 4B i) and reaching high levels by 16 dpi (not shown). On the other hand, in gray matter (Figs. 2C iii, vi, 3C , 4B ii), platelets were clearly detectable by 10 dpi and commonly observed in close association with neuronal cell bodies (Supplementary Video; Fig. 4A, F ) and in the vicinity of blood vessels (Fig. 4C ). Platelets were not observed in either the white or the gray matter in the 7-15 dpi MOG -induced/ R300-treated group (Fig. 4B iii, iv) . Double immunochemistry against serum albumin (as a marker of compromised blood-brain barrier) and platelets showed that at 10 dpi platelet infiltration in gray matter was coincident with severe albumin leakage but not inflammatory infiltration (Fig. 4D) , as evidenced by the absence of perivascular cuffs (Fig. 4A) . In support of this evidence, no albumin leakage was detectable in sections from the 7-15 dpi MOG -induced/R300-treated group (Fig. 4E i, ii) . These data confirm that platelet invasion was associated with early compromised blood-brain barrier, but ahead of inflammatory cells, in the gray matter compartment.
To further address the significance of the early entry of platelets in gray matter parenchyma, immunochemical analysis of platelets, and the platelet-specific product platelet factor 4 (PF4, or CXCL4) (32) was performed. PF4 is released during platelet activation and exhibits a wide range of proinflammatory activities. Platelet and PF4 colocalization was evident reaching a peak by 12 dpi (Fig. 4G) , namely, at the time corresponding to the peak of platelet accumulation as shown in Figure 2D .
Platelets Infiltrate the Retina From the Preclinical Stage
Optic neuritis is an early symptom in EAE, similarly to MS (24) . Therefore, to further demonstrate the key role of platelets in neuroinflammation in a clinically relevant CNS region, we examined platelets infiltration and accumulation in the retina from preclinical disease stage. In this series of experiments, immunochemical detection of platelets was performed without prior whole-body perfusion in order to avoid retinal vasculature damage as a result of perfusion pressure. In retinal flatmounts, CD42b/CD31 immunochemistry detected the presence of platelets in the vasculature of both vehicleonly-injected and EAE-induced mice (Fig. 5A-C) . However, while platelets remained confined to blood vessels in vehicleonly-injected mice, these elements were clearly seen to leak from blood vessels by 9 dpi and throughout the disease course in EAE-induced mice.
Platelet Invasion of the Retina Is Not Followed by Lymphocytic Infiltration
In the retina of EAE-induced mice, platelet accumulation was not followed by that of CD3 cells. CD42b/CD3 immunochemistry showed that at 9 dpi, no CD3-positive cells had invaded the retina, while CD42b-positive elements were already abundant in this group. By 14 dpi, while CD42b-positive immunostaining had increased, CD3 cells remained undetectable (Fig. 5D-F) . This was in contrast to the optic nerve where platelets could already be identified by 9 dpi, but not CD3 cells, while both platelets and abundant CD3 cells were present by 14 dpi (Fig. 5G,  H) . Significantly, platelet leakage in EAE-induced mice was associated with the ganglion cell layer only, as shown in coronal sections of the eyeball, which supports the notion that platelet leakage is a disease-specific phenomenon (Fig. 5E, F) . Sections from platelet-depleted animals showed absence of leakage with albumin/lectin staining. Scale bars: E i ¼ 50 mm; E ii ¼ 10 mm. (F) 3D rendering of a confocal z-stack of MOG -induced/no further treatment group tissue section shows platelets (green, arrow) associated with the neuronal soma (red). A total of 11 slices were captured digitally across a 7-mm section, with 10% overlap and a distance of 0.8 mm between each slice (Supplementary Video). (G) Presence of platelet inflammatory products was detected using anti-PF4(green) along with platelets (red) in spinal cord tissue. Scale bar: 10 mm.
Platelet Infiltration Is Associated With Abnormality in Retina Structure
To identify whether platelet presence in the retina was associated with damage to this structure, retinal thickness was measured in experimental and vehicle-only control mice. This was achieved in coronal sections of the retina and ImageJ analysis from normal, vehicle-only, and MOG -induced groups at 14 dpi. A highly significant difference in retinal thickness between MOG 35-55 -induced and vehicle-only groups was found, with MOG 35-55 -induced mice exhibiting increased thickness (Fig. 5I) .
DISCUSSION
The data presented here establish the driving role of platelets in EAE development by the identification of at least 2 distinct disease stages dependent upon platelet accumulation. First, during the preclinical stage, the key timing of platelet accumulation was demonstrated by their sudden and significant increase above control levels at 7 dpi, which is prior to the earliest detectable lymphocytic infiltration. A cause-and-effect relationship was confirmed by the complete absence of disease development upon platelet depletion ( Fig. 2A, B) , corroborated by absence of hallmarks of neuroinflammation, including lymphocytic infiltration, demyelination, and glial reactivity (Supplementary Data Fig. S1 ).
Second, platelet accumulation was rapidly followed (within 24 hours) by their entry into the parenchyma, as shown by qPCR evaluation of CD41 in total spinal cord cDNA from 8 dpi (Fig. 2D ). CD41 accumulation in the spinal cord reached a peak at 12 dpi, preceding that of CD3 which was observed at 16 dpi (Fig. 2E) . This observation, combined with that of absence of CD3 cDNA amplification in EAE-induced mice upon platelet depletion, suggest a prerequisite for amplification of platelet numbers for CD3 accumulation to ensue.
Unexpectedly, upon further examination of platelet invasion in the white and gray matter separately, using a confocal microscopic approach with combined anti-CD41/ anti-CD42b, differential associations with hallmarks of neuroinflammation were observed. In white matter, platelet infiltration exhibited a diffuse staining pattern similar to that of lymphocytic infiltration (Figs. 3B, 4B i), in agreement with the literature (16, 19) and was abundant by 12 dpi. In gray matter, on the other hand, platelet accumulation was detectable immunochemically by 10 dpi. It was clearly coincident with early blood-brain barrier loss of function and preceded inflammatory infiltration (Fig. 4D) , suggesting earlier platelet invasion in the gray matter relative to white matter. However, it is also important to bear in mind that the differential timing of the first evidence of platelet markers between qPCR and immunochemical approaches may be related to the small size of these elements and difficulty of their detection by confocal microscopy. On the other hand, of particular significance was that in contrast to the diffuse distribution of platelets in white matter, the staining pattern exhibited in gray matter demonstrated accumulation around neuronal cell bodies (Fig. 4B ii,  F) . This implication of specific association between neuronal cell bodies and platelets is in agreement with the previous demonstration of formation of lipid rafts between platelets and neurons in EAE (22) . The platelet-specific proinflammatory molecule PF4 was detected in both gray (Fig. 4G ) and white matter (not shown), suggesting that platelet presence in the CNS parenchyma is not a passive event, but part of the pathological process.
The differential roles of platelets in gray and white matter was further supported by comparison between the optic nerve and retina. In the optic nerve, similarly to observations made when examining the spinal cord, the timing of platelet infiltration preceded that of CD3 cells. These elements were widely disseminated throughout the tissue, without apparent association with any CNS elements. In the retina, platelet leakage was identified specifically in the inner retinal layer at early disease stage. Platelet infiltration was not followed by that of CD3 cells over the time course examined, but was clearly associated with retinal thickening, presumably from edema, demonstrating a relationship between retinal damage and platelets rather than CD3 cells. Similar to MS, optic neuritis is an early symptom in EAE; these data suggest differential retinal and optic nerve damage mechanisms and have relevance to the development of therapeutic approaches for visual symptoms.
Taken together, our data demonstrate that platelets drive neuroinflammation. This conclusion differs substantially from that of Langer et al (19) who suggested that platelets exacerbate, rather than drive this process. The different interpretations probably relate to the different timings of initiation of platelet depletion between the 2 investigations. In our study, platelet depletion regimens were based on the precise identification of the onset of platelet accumulation in the peripheral circulation and recovery of platelet numbers, rather than evidence of clinical disease.
The above data have relevance to MS. It is now accepted that different pathophysiological mechanisms operate in white and gray matter. While inflammatory demyelination is the hallmark of white matter disease, gray matter damage is less discernible and significantly less inflammatory, with the dominant effector cell being the microglia (33) (34) (35) . The different pathophysiology in the 2 compartments may be related to different aspects of the broad scope of platelet functions. Thus, together with evidence from the literature, our findings demonstrate a continuum of platelet involvement in neuroinflammation, beginning with a driving role in the preclinical phase of disease (this communication), probably via interactions with T cell subsets (21) . The mechanisms by which platelets promote neuroinflammation were not investigated in this study, but there is evidence that platelets regulate recruitment, activation, differentiation, and cytokine production of different CD4-positive T cell subsets (21) . Additionally, platelets have been shown to alter the permeability of the endothelial layer (2, 22, 36) , via the production of platelet-derived microparticles (37) . Finally, the evidence presented here also implicates platelets both in white and gray matter pathology, but via different pathways.
A major question arising is: What are the mechanisms underlying platelet activation and neuronal damage and their timing relative to changes on the endothelial cell surface? The elucidation of these mechanisms would provide further insight into the participation of platelets in neuroinflammation. Overall, however, our findings suggest a hitherto undescribed mechanism of gray matter pathology that is potentially therapeutically targetable given the wealth of information regarding platelet biology and treatment in other inflammatory contexts (38) .
